Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 3, 2023, to report its financial and operating results for the fourth quarter and full year ended December 31, 2022. The key details of these results are provided in a press release, which is furnished as an exhibit to this filing. Investors should refer to this press release for specific financial metrics, including revenue, earnings, and updates on key product performance and pipeline developments, which are crucial for understanding the company's current financial health and future outlook.
Key Highlights
- 1REGN filed an 8-K on February 3, 2023, providing fourth quarter and full year 2022 financial and operating results.
- 2The official announcement of these results was made via a press release dated February 3, 2023.
- 3The press release, furnished as Exhibit 99.1, contains the detailed financial and operational information.
- 4Investors are directed to the press release for comprehensive data on performance.
- 5This filing serves as the official notification mechanism for REGN's latest reported financial outcomes.
- 6The information is furnished and not deemed 'filed' for Section 18 purposes, a standard disclosure for earnings releases.